Clinical Trial Update: A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 study of enfortumab vedotin in Japanese subjects with locally advanced or metastatic urothelial carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Metastatic Urothelial Cancer | Phase 1 | Status: COMPLETED